Naoki Izawa
Overview
Explore the profile of Naoki Izawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
316
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kagawa Y, Ando K, Uemura M, Watanabe J, Oba K, Emi Y, et al.
Ann Gastroenterol Surg
. 2024 Nov;
8(6):1067-1075.
PMID: 39502728
Aim: To evaluate the feasibility and safety of total neoadjuvant therapy with long-course chemoradiotherapy followed by consolidation chemotherapy in Japanese patients with locally advanced rectal cancer. Methods: This prospective, multicenter,...
2.
Hamano J, Higashibata T, Kessoku T, Kajiura S, Hirakawa M, Oyamada S, et al.
J Clin Oncol
. 2024 Sep;
42(35):4206-4217.
PMID: 39255425
Purpose: Opioid-induced constipation is the most frequent and non-self-limiting adverse effect of opioid analgesia, reducing adherence and interfering with pain relief. This clinical trial aimed to clarify the preventive effect...
3.
Takeda H, Yamamoto H, Oikawa R, Umemoto K, Arai H, Mizukami T, et al.
JCO Precis Oncol
. 2024 Aug;
8:e2300425.
PMID: 39116356
Purpose: Panel-based comprehensive genomic profiling (CGP) is used in clinical practice worldwide; however, large real-world data (RWD) of patients with advanced small intestine cancer have not been characterized. We investigated...
4.
Katada C, Yokoyama T, Watanabe A, Hara H, Yoshii T, Fujii H, et al.
Int J Radiat Oncol Biol Phys
. 2024 Jul;
120(5):1353-1362.
PMID: 38969179
Purpose: This study aimed to assess the viability of definitive chemoradiotherapy (dCRT) as an organ-preservation strategy for remarkable responders who were downstaged to stage IA after receiving induction chemotherapy for...
5.
Minatogawa H, Izawa N, Nakajima T
Br J Cancer
. 2024 May;
130(12):1887-1888.
PMID: 38750116
No abstract available.
6.
Yamamoto H, Arai H, Oikawa R, Umemoto K, Takeda H, Mizukami T, et al.
Target Oncol
. 2024 Apr;
19(3):459-471.
PMID: 38613733
Background: Panel-based comprehensive genomic profiling is used in clinical practice worldwide; however, large real-world datasets of patients with advanced gastric cancer are not well known. Objective: We investigated what differences...
7.
Kotani D, Takashima A, Kato T, Satoh T, Masuishi T, Komatsu Y, et al.
Clin Colorectal Cancer
. 2024 Mar;
23(2):174-182.e6.
PMID: 38553360
Background: The phase 3 BEACON CRC study demonstrated the survival benefits of encorafenib and cetuximab, with or without binimetinib (the BEACON triplet or doublet regimen), for BRAF-mutant metastatic colorectal cancer...
8.
Matsumoto T, Yamamoto Y, Kotaka M, Masuishi T, Tsuji Y, Shoji H, et al.
Target Oncol
. 2024 Mar;
19(2):181-190.
PMID: 38427280
Background: Non-inferiority of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) to irinotecan/fluoropyrimidine plus BEV in metastatic colorectal cancer was investigated in the phase III TRUSTY study, and we conducted a phase II...
9.
Arai H, Yang Y, Baca Y, Millstein J, Denda T, Ou F, et al.
Eur J Cancer
. 2024 Feb;
201:113914.
PMID: 38359495
Background: CDC37 is a key determinant of client kinase recruitment to the HSP90 chaperoning system. We hypothesized that kinase-specific dependency on CDC37 alters the efficacy of targeted therapies for metastatic...
10.
Minatogawa H, Izawa N, Shimomura K, Arioka H, Iihara H, Sugawara M, et al.
Br J Cancer
. 2023 Nov;
130(2):224-232.
PMID: 37973958
Background: This study evaluated the non-inferiority of dexamethasone (DEX) on day 1, with sparing on days 2-4 in cisplatin-based chemotherapy. Methods: Patients with malignant solid tumors who were treated with...